<< Back To Search

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
The study is testing a new drug called HPN217 to see if it is safe to use and how it affects people with multiple myeloma that did not get better with other treatments. They will also be looking at how the body absorbs and gets rid of the drug.
*Third Opinion AI Generated Synopsis

Trial Summary
An open-label, Phase 1 study of HPN217 to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?